Association of Serum Thromboinflammatory Biomarkers With Atherosclerotic Plaques and Burden in a Community-Based

Baoshan Qiu1,2,3, Xueli Cai4, Lebo Zhou1,2

  • 1Department of Neurology, Beijing Tiantan Hospital (B.Q., L.Z., X.W., N.W., L.J., J.J., Yongjun Wang, Y.P., Yilong Wang), Capital Medical University, China.

Insights

Higher levels of soluble glycoprotein VI (sGPVI) were linked to increased coronary atherosclerosis, while higher levels of soluble ADAMTS13 (sADAMTS13) were associated with reduced coronary plaque burden. No links were found for other assessed biomarkers or plaque locations.

Area of Science:

  • Cardiovascular Science
  • Biomarker Research
  • Inflammation Studies

Background:

  • Atherosclerosis pathogenesis involves inflammation and thromboinflammation.
  • Investigating thromboinflammatory biomarkers in relation to atherosclerotic plaques is crucial for understanding disease progression.

Purpose of the Study:

  • To investigate the association between circulating thromboinflammatory biomarkers and atherosclerotic plaques.
  • To determine the relationship between serum levels of sGPVI, sADAMTS13, sP-selectin, and the presence and burden of coronary, intracranial, and extracranial atherosclerosis.

Main Methods:

  • Analysis of 3019 participants (aged 50-75) from the PRECISE study.
  • Serum biomarker levels (sGPVI, sADAMTS13, sP-selectin) measured via ELISA and Luminex assays.
  • Coronary, intracranial, and extracranial atherosclerosis assessed using CT angiography and MRI.

Main Results:

  • Elevated sGPVI levels correlated with higher coronary atherosclerotic plaque burden.
  • Higher sADAMTS13 levels were associated with lower odds of coronary plaques and reduced plaque burden.
  • No significant associations were found between sGPVI, sADAMTS13, or sP-selectin and intracranial or extracranial atherosclerosis.

Conclusions:

  • Serum sADAMTS13 levels are negatively associated with coronary atherosclerosis presence and burden.
  • Serum sGPVI levels are positively associated with coronary atherosclerosis burden.
  • Thromboinflammatory biomarkers showed no significant association with intracranial or extracranial atherosclerosis in this cohort.
Abstract

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
41
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
128
Inflammation01:38

Inflammation

Overview
55.4K